France to reimburse weight-loss drugs for severely obese patients

France will begin reimbursing prescription weight-loss drugs for severely obese patients on 15 June, making it the first European Union country to use public insurance to pay for modern anti-obesity medicines. Health Minister Stéphanie Rist said the move would cover injectable treatments including Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro, shifting the drugs from a largely out-of-pocket expense into the health system’s mainstream.

The policy is tightly targeted. It will apply to patients with a body mass index of at least 35 plus at least one comorbidity, or a BMI of at least 40 regardless of other conditions. Rist estimated the program could cost about 100 million euros a year at full rollout, while the potential target population could reach about one million people. Not all of them will qualify, because access will depend on individual medical assessment and a doctor’s prescription.

For patients who now pay around 300 euros a month on average, reimbursement could sharply reduce the cost barrier to treatment. That matters in a country where obesity is estimated to affect about 18 percent of the population, or roughly one in five adults. Anti-obesity drugs have been available by prescription in France since 2024, but public coverage changes the policy calculus: the question is no longer whether these drugs exist, but how broadly a national health system should pay for them.

The decision also lands as drugmakers press for wider acceptance of GLP-1 medicines as chronic-disease therapies rather than niche lifestyle products. Novo Nordisk and Eli Lilly both welcomed the French move, and the policy gives France a place at the center of a fast-moving European debate over cost, access and long-term outcomes. Health ministries elsewhere will be watching whether public reimbursement lowers hospitalizations, improves weight-loss outcomes and proves affordable enough to justify expansion beyond the most severe cases.

The timing is notable as Europe inches toward an even broader shift in obesity treatment. On 21 May, the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending an oral tablet version of Wegovy for EU approval in four strengths, which would make it the first oral GLP-1 obesity treatment recommended for use in the bloc. If France’s reimbursement model holds, it could become the first large-scale European test of whether governments treat obesity drugs as a public-health investment, not a luxury therapy. U.S. insurers and policymakers will be watching the same numbers: who qualifies, what it costs and whether coverage delivers measurable health gains.